Results 11 to 20 of about 76,225 (259)
Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance [PDF]
, 2021 Hemagglutinin and neuraminidase, which constitute the glycoprotein spikes expressed on the surface of influenza A and B viruses, are the most exposed parts of the virus and play critical roles in the viral lifecycle.
Sook-San Wong +7 more
core +1 more source
Recent Advances in Antivirals for Japanese Encephalitis Virus
, 2023 Culex mosquitoes are the primary vectors of the Japanese encephalitis virus (JEV). Since its discovery in 1935, Japanese encephalitis (JE), caused by JEV, has posed a significant threat to human health.
Zhongtian Qi +3 more
core +1 more source
Extracellular Polymeric Substances: Still Promising Antivirals
, 2022 Sulfated polysaccharides and other polyanions have been promising candidates in antiviral research for decades. These substances gained attention as antivirals when they demonstrated a high inhibitory effect in vitro against human immunodeficiency virus (
López-Guerrero, José Antonio +9 more
core +1 more source
β-Cyclodextrins as affordable antivirals to treat coronavirus infection [PDF]
, 2023 The SARS-CoV-2 pandemic made evident that there are only a few drugs against coronavirus. Here we aimed to identify a cost-effective antiviral with broad spectrum activity and high safety profile.
Roca, Núria +60 more
core +1 more source
HCMV Antivirals and Strategies to Target the Latent Reservoir
, 2021 Human cytomegalovirus (HCMV) is a ubiquitous human herpesvirus. In healthy people, primary infection is generally asymptomatic, and the virus can go on to establish lifelong latency in cells of the myeloid lineage.
Mark R. Wills +2 more
core +1 more source
, 2022 Rocaglates are potent broad-spectrum antiviral compounds with a promising safety profile. They inhibit viral protein synthesis for different RNA viruses by clamping the 5′-UTRs of mRNAs onto the surface of the RNA helicase eIF4A.
Klemm, P. +25 more
core +1 more source
Structure-based design of antivirals against Envelope Glycoprotein of dengue virus [PDF]
, 2020 Dengue virus (DENV) presents a significant threat to global public health with more than 500,000 hospitalizations and 25,000 deaths annually. Currently, there is no clinically approved antiviral drug to treat DENV infection. The envelope (E) glycoprotein
Anasir, M. I. * +5 more
core +1 more source
Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19 [PDF]
, 2022 Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals.
Giotta, Massimo +17 more
core +1 more source
, 2023 In patients with multiple myeloma (MM), SARS-CoV-2 infection has been associated with a severe clinical course and high mortality rates due to the concomitant disease- and treatment-related immunosuppression.
Maria Gavriatopoulou +11 more
core +1 more source
Nano-antivirals: A comprehensive review [PDF]
, 2022 Nanoparticles can be used as inhibitory agents against various microorganisms, including bacteria, algae, archaea, fungi, and a huge class of viruses. The mechanism of action includes inhibiting the function of the cell membrane/stopping the synthesis of
Saima Q. Memon +4 more
core +1 more source